Stock Scorecard
Stock Summary for BioAtla Inc (BCAB) - $0.87 as of 11/24/2025 8:07:09 PM EST
Total Score
10 out of 30
Safety Score
21 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for BCAB
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for BCAB
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for BCAB
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for BCAB
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for BCAB (21 out of 100)
| Stock Price Rating (Max of 10) | 1 |
| Historical Stock Price Rating (Max of 10) | 6 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 2 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for BCAB
Financial Details for BCAB
Company Overview |
|
|---|---|
| Ticker | BCAB |
| Company Name | BioAtla Inc |
| Country | USA |
| Description | BioAtla, Inc. is a cutting-edge biopharmaceutical firm headquartered in San Diego, California, dedicated to advancing antibody-based therapies for various cancer indications. Leveraging its proprietary Bispecific T cell Engager (BiTEx™) technology, BioAtla is at the forefront of developing innovative treatments designed to selectively target and eradicate cancer cells while preserving healthy tissue. With a strong commitment to addressing critical unmet needs in oncology, the company boasts a promising pipeline of product candidates that positions it as a key player in the rapidly evolving oncology therapeutics market. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 0.87 |
| Price 4 Years Ago | 19.63 |
| Last Day Price Updated | 11/24/2025 8:07:09 PM EST |
| Last Day Volume | 4,168,317 |
| Average Daily Volume | 1,848,193 |
| 52-Week High | 1.74 |
| 52-Week Low | 0.24 |
| Last Price to 52 Week Low | 262.50% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 43.52 |
| Sector PE | 86.12 |
| 5-Year Average PE | -2.46 |
| Free Cash Flow Ratio | 6.21 |
| Industry Free Cash Flow Ratio | 13.25 |
| Sector Free Cash Flow Ratio | 27.29 |
| Current Ratio Most Recent Quarter | 0.54 |
| Total Cash Per Share | 0.14 |
| Book Value Per Share Most Recent Quarter | -0.53 |
| Price to Book Ratio | 2.68 |
| Industry Price to Book Ratio | 34.10 |
| Sector Price to Book Ratio | 33.20 |
| Price to Sales Ratio Twelve Trailing Months | 4.22 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.97 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.80 |
| Analyst Buy Ratings | 1 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 58,792,000 |
| Market Capitalization | 51,149,040 |
| Institutional Ownership | 28.73% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 43.48% |
| Reported EPS 12 Trailing Months | -1.15 |
| Reported EPS Past Year | -0.85 |
| Reported EPS Prior Year | -1.44 |
| Net Income Twelve Trailing Months | -64,707,000 |
| Net Income Past Year | -69,776,000 |
| Net Income Prior Year | -123,462,000 |
| Quarterly Revenue Growth YOY | 31.60% |
| 5-Year Revenue Growth | 16.17% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 8,320,000 |
| Total Cash Past Year | 49,046,000 |
| Total Cash Prior Year | 111,471,000 |
| Net Cash Position Most Recent Quarter | 8,320,000 |
| Net Cash Position Past Year | 48,364,000 |
| Long Term Debt Past Year | 682,000 |
| Long Term Debt Prior Year | 682,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.95 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | 14,265,000 |
| Total Stockholder Equity Prior Year | 70,672,000 |
| Total Stockholder Equity Most Recent Quarter | -31,237,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -71,348,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.21 |
| Free Cash Flow Past Year | -71,936,000 |
| Free Cash Flow Prior Year | -104,113,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.09 |
| MACD Signal | 0.03 |
| 20-Day Bollinger Lower Band | 0.15 |
| 20-Day Bollinger Middle Band | 0.60 |
| 20-Day Bollinger Upper Band | 1.05 |
| Beta | 1.03 |
| RSI | 67.52 |
| 50-Day SMA | 0.53 |
| 150-Day SMA | 1.83 |
| 200-Day SMA | 2.91 |
System |
|
| Modified | 11/24/2025 6:25:39 PM EST |